×
Hero Background

Whipple’s Disease Companies

ID: MRFR/HC/2762-HCR
200 Pages
Rahul Gotadki
October 2025

Whipple's disease is a rare infectious disorder caused by the bacterium Tropheryma whipplei. It primarily affects the small intestine but can also involve other organs. The treatment typically involves a prolonged course of antibiotics.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Top Industry Leaders in the Whipple’s Disease Market

Whipple

 


Latest Whipple’s Disease Companies Updates:


Grifols Their TAURINOX (sodium taurocholate) received orphan drug designation in the US and EU for treating Whipple's disease, potentially streamlining the approval process.


Takeda Pharmaceuticals Their investigational drug, Entyvio (vedolizumab), is undergoing clinical trials for potential use in Whipple's disease, exploring alternative treatment options.


Roche Diagnostics Launched a new PCR test for detecting Tropheryma whipplei bacteria, the causative agent of Whipple's disease, aimed at improving diagnostic accuracy and speed.


BioFire Diagnostics Their FilmArray Gastrointestinal Panel 2.0 now includes a test for T. whipplei, providing a broader diagnostic tool for gastroenterologists.


List of Whipple’s Disease  Key companies in the market:



  • AbbVie Inc. (US)

  • Allergan (Republic of Ireland)

  • Bayer AG (Germany)

  • Bristol-Myers Squibb Company (US)

  • F. Hoffmann-La Roche Ltd. (Switzerland)

  • Henry Schein, Inc (US)

  • Pfizer Inc. (US)